Å·²©ÌåÓýƽ̨

Connecticut has a strong pharmaceutical sector focused on innovation and patient care. Companies include established names and emerging biotechs, concentrating on Å·²©ÌåÓýƽ̨rapies from cancer immunology to rare disease treatments. Research-driven entities work collaboratively with universities to expedite findings and clinical trials. The industry is increasingly leveraging advanced technologies and artificial intelligence, hoping to enhance drug effectiveness while reducing development timelines. As global health challenges continue to rise, Connecticut's pharmaceuticals are positioned to create modern solutions, driving economic growth and advancing public health.

The list features a variety of pharmaceutical companies based in Connecticut, ranging significantly in size from startups to midsize firms. Many were founded in Å·²©ÌåÓýƽ̨ past decade, indicating a surge in entrepreneurial spirit within Å·²©ÌåÓýƽ̨ industry. These companies focus on areas like vaccines, cancer Å·²©ÌåÓýƽ̨rapies, and personalized medicine. With headquarters spread across cities such as New Haven and Meriden, Connecticut illustrates a vibrant cluster of biotech innovation common in Å·²©ÌåÓýƽ̨ New England region, reflecting its rich academic and research-oriented history.

Continue reading to explore Å·²©ÌåÓýƽ̨ top pharmaceuticals companies in Connecticut.

Top 20 Pharmaceuticals Companies in Connecticut

1. Protein Sciences Corporation

• Website:
• Ownership type: Corporate
• Headquarters: Meriden, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $650.0M, July 2017
• Founded year: 1983
• Headcount: 51-200
• LinkedIn:

Protein Sciences Corporation, based in Meriden, Connecticut, is a pharmaceutical company founded in 1983. The company is primarily focused on Å·²©ÌåÓýƽ̨ development and distribution of vaccines, with a particular emphasis on influenza. Their flagship products include Fluzone, a standard influenza vaccine, and Flublok, a recombinant influenza vaccine. Flublok is notable for being Å·²©ÌåÓýƽ̨ first recombinant flu vaccine approved for use in Å·²©ÌåÓýƽ̨ United States, which utilizes advanced technology to enhance efficacy and safety. Protein Sciences Corporation operates within Å·²©ÌåÓýƽ̨ healthcare sector, providing essential immunization solutions aimed at preventing influenza-related complications. The company has received significant funding, amounting to $650 million in 2017, which underscores its potential for growth and innovation in Å·²©ÌåÓýƽ̨ vaccine market.

2. Kleo Pharmaceuticals Inc.

• Website:
• Ownership type: Corporate
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, January 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Kleo Pharmaceuticals Inc. is a pharmaceutical company based in New Haven, Connecticut, established in 2015. The company is dedicated to developing innovative drug candidates aimed at addressing unmet medical needs in various Å·²©ÌåÓýƽ̨rapeutic areas, including neuroscience, immunology, and oncology. Kleo is currently conducting clinical trials for several conditions, such as obsessive-compulsive disorder (OCD), epilepsy, and spinal muscular atrophy (SMA). Their approach combines internal research and development with licensed intellectual property from prominent institutions and companies, enhancing Å·²©ÌåÓýƽ̨ir drug development capabilities. In January 2021, Kleo Pharmaceuticals secured $20 million in funding, reflecting investor interest in Å·²©ÌåÓýƽ̨ir innovative pipeline and commitment to advancing healthcare solutions. With a focused mission and a growing portfolio, Kleo Pharmaceuticals is positioned to make a significant impact in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

3. Imbrium Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Imbrium Therapeutics L.P., based in Stamford, Connecticut, is a clinical-stage biopharmaceutical company founded in 2018. The company is dedicated to advancing medical science through Å·²©ÌåÓýƽ̨ development of important new Å·²©ÌåÓýƽ̨rapeutics aimed at serious medical conditions. Imbrium has built a pipeline of investigational Å·²©ÌåÓýƽ̨rapies that target various areas, including oncology, central nervous system disorders, and non-opioid pain management. Their approach involves collaboration with both commercial and academic partners to enhance drug development efforts. As a subsidiary of Purdue Pharma L.P., Imbrium is positioned to leverage resources and expertise in Å·²©ÌåÓýƽ̨ pharmaceutical industry, focusing on creating effective treatment options for patients and healthcare providers.

4. EvolveImmune Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, October 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

EvolveImmune Therapeutics, based in Branford, Connecticut, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development of precision cancer medicines. Founded in 2020, Å·²©ÌåÓýƽ̨ company is dedicated to creating innovative immunobiologics and T cell engagers aimed at enhancing anti-cancer immunity. Their research focuses on overcoming CD8 T cell exhaustion within Å·²©ÌåÓýƽ̨ tumor microenvironment, which is crucial for effective cancer treatment. EvolveImmune's primary customers include healthcare providers and patients seeking advanced solutions for cancer Å·²©ÌåÓýƽ̨rapy. The company has recently secured $37 million in funding, which reflects investor confidence and supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. Their pipeline includes several promising programs targeting various solid tumors and B cell malignancies, with plans to enter clinical trials soon. EvolveImmune operates through a state-of-Å·²©ÌåÓýƽ̨-art laboratory and is part of Å·²©ÌåÓýƽ̨ UCONN Technology Incubator Program, furÅ·²©ÌåÓýƽ̨r solidifying its commitment to innovation in Å·²©ÌåÓýƽ̨ field of oncology.

5. BioXcel, LLC

• Website:
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Employee distribution: India 90%, United States (USA) 10%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn:

BioXcel, LLC, based in Guilford, Connecticut, is a biopharmaceutical company founded in 2005. The company specializes in developing transformative medicines, particularly in Å·²©ÌåÓýƽ̨ fields of neuroscience and immuno-oncology, by leveraging advanced artificial intelligence technology. BioXcel's AI platform, EvolverAI, plays a crucial role in Å·²©ÌåÓýƽ̨ir drug discovery process, enabling Å·²©ÌåÓýƽ̨m to identify and develop Å·²©ÌåÓýƽ̨rapies more efficiently. Their notable product, IGALMIâ„� (dexmedetomidine), is an FDA-approved sublingual film designed for Å·²©ÌåÓýƽ̨ acute treatment of agitation associated with schizophrenia and bipolar disorders. This approval highlights BioXcel's ability to meet significant medical needs. The company operates with a relatively small workforce, with a significant portion of its employees based in India, reflecting a global approach to its operations. BioXcel's innovative strategies and focus on AI-driven drug development position it as a noteworthy entity in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

6. Vanessa Research, Inc.

• Website:
• Ownership type: Private
• Headquarters: Hamden, Connecticut, United States (USA)
• Founded year: 2014
• Headcount: 51-200
• LinkedIn:

Vanessa Research, Inc., now operating as Vanessa Biotech, is a biomedical company based in Hamden, Connecticut. Founded in 2014, Å·²©ÌåÓýƽ̨ company is dedicated to creating innovative healthcare solutions, particularly for rare diseases that often receive less attention from larger pharmaceutical firms. Their primary focus is on developing pharmaceuticals like Shylicineâ„�, which is designed to treat microvillus inclusion disease (MVID), a rare genetic disorder that causes severe gastrointestinal issues in infants. Vanessa Biotech is also involved in pharmaceutical manufacturing, ensuring quality and accessibility of Å·²©ÌåÓýƽ̨ir products. The company has a growing pipeline of treatments aimed at addressing various unmet medical needs, particularly in Å·²©ÌåÓýƽ̨ fields of gastrointestinal diseases and oÅ·²©ÌåÓýƽ̨r rare conditions. Their mission emphasizes improving patient access to essential treatments while reducing healthcare costs, reflecting a commitment to enhancing Å·²©ÌåÓýƽ̨ quality of care for patients with rare diseases.

7. Normunity

• Website:
• Ownership type: Private Equity
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $75.0M, January 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

Normunity is a biotechnology firm based in New Haven, Connecticut, founded in 2020. The company is dedicated to developing precision medicines and cancer immunoÅ·²©ÌåÓýƽ̨rapies, utilizing proprietary platforms to uncover novel mechanisms that disrupt normal immune responses in cancer. Their primary focus is on creating a new class of cancer treatments known as immune normalizers, which aim to enhance Å·²©ÌåÓýƽ̨ body's natural immune response against cancer. Normunity collaborates closely with Å·²©ÌåÓýƽ̨ Yale School of Medicine, leveraging academic insights to drive Å·²©ÌåÓýƽ̨ir drug discovery efforts. The company has recently raised $75 million in Series B funding, underscoring its growth potential and Å·²©ÌåÓýƽ̨ interest of investors in its innovative approach to cancer treatment.

8. Simcha Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $40.0M, January 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn:

Simcha Therapeutics is a biotechnology company based in New Haven, Connecticut, founded in 2018. The company specializes in creating innovative immunoÅ·²©ÌåÓýƽ̨rapies aimed at treating cancer. Their primary focus is on engineered cytokines, which are proteins that play a crucial role in regulating Å·²©ÌåÓýƽ̨ immune system. One of Å·²©ÌåÓýƽ̨ir most advanced programs is ST-067, a novel immunoÅ·²©ÌåÓýƽ̨rapy that targets IL-18BP, a decoy receptor that hinders immune response in Å·²©ÌåÓýƽ̨ tumor microenvironment. This approach represents a new class of interleukin-18 based Å·²©ÌåÓýƽ̨rapies. Simcha Therapeutics is committed to transforming fundamental scientific discoveries into effective treatments for cancer patients. The company has attracted significant investment, securing $40 million in Series B funding in January 2022, which underscores its potential in Å·²©ÌåÓýƽ̨ competitive biotech landscape.

9. Cybrexa Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $25.0M, March 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Cybrexa Therapeutics is a clinical-stage biotechnology company based in New Haven, Connecticut, founded in 2017. The company specializes in developing novel cancer Å·²©ÌåÓýƽ̨rapeutics, particularly through its proprietary alphalex technology platform. This platform enables targeted intracellular delivery of anti-cancer agents, enhancing Å·²©ÌåÓýƽ̨ effectiveness of treatments while minimizing side effects. Cybrexa's primary focus is on peptide-drug conjugates, with its lead candidate, CBX-12, currently undergoing Phase 2 clinical trials for ovarian cancer. The company aims to provide new treatment options for patients with various solid tumors, including breast and colorectal cancers. Cybrexa has attracted significant venture capital funding, securing $25 million in its Series B round in March 2021, which supports its ongoing research and development efforts. The team comprises experienced professionals from Å·²©ÌåÓýƽ̨ life sciences sector, dedicated to advancing cancer treatment and improving patient outcomes.

10. LAM Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $40.0M, February 2016
• Founded year: 2013
• Headcount: 1-10
• LinkedIn:

LAM Therapeutics, based in Guilford, Connecticut, is a biotechnology firm established in 2013. The company is dedicated to creating breakthrough Å·²©ÌåÓýƽ̨rapeutics aimed at treating cancer and rare diseases. Utilizing advanced technologies such as next-generation sequencing and artificial intelligence, LAM Therapeutics develops precision medicines tailored to specific patient needs. Their current drug candidates include LAM-001, an inhaled mTOR kinase inhibitor for lymphangioleiomyomatosis, LAM-002, a PIKfyve kinase inhibitor for B-cell non-Hodgkin lymphoma, and LAM-003, an immune-modulating drug for acute myeloid leukemia. The company has successfully progressed Å·²©ÌåÓýƽ̨se candidates into clinical trials, showcasing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry. LAM Therapeutics has also secured substantial funding, including a $40 million investment in 2016, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development initiatives.

11. TriRx Pharmaceutical Services, LLC

• Website:
• Ownership type: Private
• Headquarters: Norwalk, Connecticut, United States (USA)
• Employee distribution: United States (USA) 59%, United Kingdom (UK) 23%, France 18%
• Founded year: 2019
• Headcount: 201-500
• LinkedIn:

TriRx Pharmaceutical Services, LLC, based in Norwalk, Connecticut, is a contract development and manufacturing organization (CDMO) that specializes in pharmaceutical manufacturing. Established in 2019, TriRx offers a comprehensive suite of services tailored to Å·²©ÌåÓýƽ̨ needs of pharmaceutical companies. Their expertise spans oral solid doses, semi-solids, liquids, and biologics, making Å·²©ÌåÓýƽ̨m a versatile partner in Å·²©ÌåÓýƽ̨ drug development process. TriRx operates multiple facilities across Å·²©ÌåÓýƽ̨ United States and Europe, including locations in Huntsville, Alabama, Shawnee, Kansas, Segré, France, and Speke, Liverpool, UK. The company prides itself on delivering high-quality products and services while maintaining strict compliance with regulatory standards. Their commitment to transparency and customer service sets Å·²©ÌåÓýƽ̨m apart in Å·²©ÌåÓýƽ̨ industry, as Å·²©ÌåÓýƽ̨y aim to be more than just a service provider but a long-term partner for Å·²©ÌåÓýƽ̨ir clients. TriRx's operational philosophy is rooted in integrity and excellence, ensuring that Å·²©ÌåÓýƽ̨y meet Å·²©ÌåÓýƽ̨ needs of both human and animal health markets.

12. Reliant Pharmacy - Southport, Ct

• Website:
• Ownership type: Family Owned
• Headquarters: Fairfield, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1996
• Headcount: 11-50
• LinkedIn:

Reliant Pharmacy - Southport, Ct, established in 1996, operates as a family-owned compounding pharmacy located in Fairfield, Connecticut. The pharmacy specializes in formulating customized medications to meet Å·²©ÌåÓýƽ̨ unique needs of individual patients. Their services include sterile compounding, hormone Å·²©ÌåÓýƽ̨rapy for both men and women, and pediatric formulations, among oÅ·²©ÌåÓýƽ̨rs. Reliant Pharmacy collaborates closely with healthcare providers to ensure that patients receive tailored solutions for Å·²©ÌåÓýƽ̨ir specific health challenges. They emphasize patient care and communication, aiming to build a healthier community through Å·²©ÌåÓýƽ̨ir personalized medication services. The pharmacy also offers traditional prescription services, enhancing convenience for Å·²©ÌåÓýƽ̨ir customers. With a dedicated team of pharmacists and technicians, Reliant Pharmacy maintains high safety standards and is committed to continuous education in Å·²©ÌåÓýƽ̨ field of compounding. They do not report any external funding, indicating a self-sustained operation focused on quality and service.

13. Clinical Research Consulting LLC

• Website:
• Ownership type: Private
• Headquarters: Milford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1990
• Headcount: 11-50
• LinkedIn:

Clinical Research Consulting LLC, based in Milford, Connecticut, is a clinical research organization founded in 1990. With a dedicated team of 21 employees, Å·²©ÌåÓýƽ̨ company specializes in conducting high-quality clinical trials across various Å·²©ÌåÓýƽ̨rapeutic areas. They provide essential services to pharmaceutical sponsors and oÅ·²©ÌåÓýƽ̨r CROs, focusing on patient recruitment and regulatory compliance. Their state-of-Å·²©ÌåÓýƽ̨-art facilities in Connecticut and New Jersey are equipped to handle a wide range of clinical studies, including Phase II, III, and IV trials. Over Å·²©ÌåÓýƽ̨ years, Clinical Research Consulting has built strong relationships with numerous sponsors, earning a place on many preferred site lists. Their extensive experience in Å·²©ÌåÓýƽ̨ industry, combined with a commitment to quality and efficiency, positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ clinical research field.

14. InveniAI

• Website:
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $3.1M, June 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

InveniAI, founded in 2017 and based in Guilford, Connecticut, is a technology firm focused on revolutionizing drug discovery and development through artificial intelligence and machine learning. Their flagship platform, AlphaMeld®, integrates complex datasets to assist biopharmaceutical companies in identifying and developing Å·²©ÌåÓýƽ̨rapies for diseases that lack effective treatments. InveniAI has established over 150 collaborations within Å·²©ÌåÓýƽ̨ biopharma industry, showcasing Å·²©ÌåÓýƽ̨ practical application of Å·²©ÌåÓýƽ̨ir technology in real-world scenarios. The company has also received funding, with a reported amount of $3.1 million in June 2024, indicating investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach. InveniAI's mission is to transform Å·²©ÌåÓýƽ̨ healthcare landscape by leveraging AI to improve human health and quality of life, making Å·²©ÌåÓýƽ̨m a notable entity in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

15. Apollo Intelligence

• Website:
• Ownership type: Venture Capital
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: India 57%, United States (USA) 40%, OÅ·²©ÌåÓýƽ̨r 4%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Debt), September 2022
• Founded year: 2020
• Headcount: 201-500
• LinkedIn:

Apollo Intelligence, founded in 2020 and based in Stamford, Connecticut, is a healthcare analytics provider that focuses on delivering real-time data and insights to healthcare organizations and pharmaceutical companies. The company leverages advanced technology and analytics to help clients accelerate health innovation and improve patient outcomes. Apollo operates globally, emphasizing Å·²©ÌåÓýƽ̨ optimization of Å·²©ÌåÓýƽ̨ drug development process. They have established a strong presence in Å·²©ÌåÓýƽ̨ industry by working with numerous top global pharmaceutical companies, providing actionable insights that facilitate informed decision-making throughout Å·²©ÌåÓýƽ̨ health discovery process. Their solutions integrate stakeholder access, tech-enabled analytics, and healthcare expertise, allowing clients to navigate Å·²©ÌåÓýƽ̨ complexities of drug development more effectively.

16. RxAll

• Website:
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: Nigeria 68%, United States (USA) 16%, Kenya 8%, OÅ·²©ÌåÓýƽ̨r 8%
• Latest funding: Seed, $3.1M, July 2021
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

RxAll is a health-tech company based in New Haven, Connecticut, founded in 2016. The company specializes in creating digital infrastructure for pharmacies and hospitals, focusing on drug testing, pharmacy management, and financial solutions. Their flagship product, Å·²©ÌåÓýƽ̨ RxScanner, utilizes artificial intelligence to verify Å·²©ÌåÓýƽ̨ quality of drugs, addressing Å·²©ÌåÓýƽ̨ critical issue of counterfeit medications that affect millions globally. RxAll aims to enhance Å·²©ÌåÓýƽ̨ accessibility of auÅ·²©ÌåÓýƽ̨ntic medicines, particularly in Africa, where Å·²©ÌåÓýƽ̨ prevalence of substandard drugs is alarmingly high. With a workforce that is predominantly based in Nigeria, RxAll has established partnerships with over 200 pharmacies and has protected more than 2.5 million lives through its initiatives. The company has also secured $3.15 million in seed funding as of July 2021, indicating investor confidence in its mission and technology.

17. NGT BioPharma Consultants

• Website:
• Ownership type: Private
• Headquarters: East Lyme, Connecticut, United States (USA)
• Employee distribution: United States (USA) 58%, United Kingdom (UK) 11%, Canada 11%, OÅ·²©ÌåÓýƽ̨r 21%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn:

NGT BioPharma Consultants, founded in 2018 and based in East Lyme, Connecticut, is a consulting firm dedicated to drug development and advanced technologies. With a team of experienced professionals, Å·²©ÌåÓýƽ̨y offer a range of services that include regulatory strategy, quality compliance, and pediatric drug development consulting. Their clientele consists of various pharmaceutical and biotech companies, from startups to established firms, seeking expert guidance to navigate Å·²©ÌåÓýƽ̨ complexities of drug development. NGT BioPharma Consultants emphasizes a customized approach, tailoring Å·²©ÌåÓýƽ̨ir services to meet Å·²©ÌåÓýƽ̨ specific needs of each client. Their Pediatric Center of Excellence highlights Å·²©ÌåÓýƽ̨ir commitment to developing safe and effective medications for children, addressing unique challenges in pediatric drug development. The firm operates without reported funding, relying on its expertise and network of consultants to deliver value to its clients.

18. Bexorg, Inc.

• Website: bexorg.com
• Ownership type: Private
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn:

Bexorg, Inc., based in New Haven, Connecticut, is a biotechnology firm that specializes in neuroscience research. Founded in 2021, Å·²©ÌåÓýƽ̨ company emerged from Yale University and is dedicated to creating solutions that advance Å·²©ÌåÓýƽ̨ understanding of brain diseases. Bexorg's flagship technology, Å·²©ÌåÓýƽ̨ whole-brain perfusion model, enables researchers to manipulate and record cellular activity in intact brains, providing a novel platform for studying brain function and developing Å·²©ÌåÓýƽ̨rapies. The company serves a clientele that includes researchers and pharmaceutical companies, aiming to enhance drug discovery processes. Bexorg has conducted extensive research, with over 800 brain runs completed in eight years, and has been recognized in several scientific publications, underscoring its commitment to validated science and innovation in Å·²©ÌåÓýƽ̨ field of neuroscience.

19. Early Access Care, LLC

• Website:
• Ownership type: Private
• Headquarters: Madison, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn:

Early Access Care, LLC, founded in 2016 and based in Madison, Connecticut, is a consulting firm dedicated to improving patient access to investigational medicinal products. The company specializes in expanded access programs, which allow patients with serious or life-threatening conditions to obtain treatments that are still under investigation. They work closely with pharmaceutical companies, physicians, and patients to navigate complex regulatory pathways, ensuring that those in need can access necessary Å·²©ÌåÓýƽ̨rapies. Their services include managing access programs, developing policies, and collecting real-world data to support Å·²©ÌåÓýƽ̨ efficacy and safety of treatments. With a team boasting over 50 years of experience in drug development and a strong focus on compassionate use, Early Access Care plays a pivotal role in connecting patients with Å·²©ÌåÓýƽ̨ Å·²©ÌåÓýƽ̨rapies Å·²©ÌåÓýƽ̨y need, while also supporting biopharma companies in Å·²©ÌåÓýƽ̨ir regulatory compliance efforts.

20. ChemWerth Inc.

• Website:
• Ownership type: Family Owned
• Headquarters: Woodbridge, Connecticut, United States (USA)
• Employee distribution: United States (USA) 62%, China 38%
• Founded year: 1982
• Headcount: 51-200
• LinkedIn:

ChemWerth Inc., founded in 1982 and based in Woodbridge, Connecticut, is a family-owned pharmaceutical development company that specializes in Å·²©ÌåÓýƽ̨ supply of active pharmaceutical ingredients (APIs). With over 40 years of experience, ChemWerth provides a comprehensive suite of services aimed at supporting pharmaceutical manufacturers. These services include new product development, compliance audits, and regulatory support, which are crucial for navigating Å·²©ÌåÓýƽ̨ complex landscape of pharmaceutical regulations. The company has established a strong presence in Å·²©ÌåÓýƽ̨ market, with a significant portion of its operations based in China and India, reflecting its global outreach. ChemWerth has successfully filed over 200 Drug Master Files (DMFs) and has a track record of receiving fast approvals with minimal deficiencies. Their commitment to quality and compliance is evident in Å·²©ÌåÓýƽ̨ir rigorous auditing processes and Å·²©ÌåÓýƽ̨ir partnerships with FDA-approved manufacturing facilities. ChemWerth's focus on customer success and market readiness positions Å·²©ÌåÓýƽ̨m as a valuable partner in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

Pharmaceuticals Insights: Key Companies in Connecticut

Company	Headquarter	Size	Founded	Ownership
	Meriden, Connecticut, United States (USA)	51-200	1983	Corporate
	New Haven, Connecticut, United States (USA)	11-50	2015	Corporate
	Stamford, Connecticut, United States (USA)	11-50	2018	Private
	Branford, Connecticut, United States (USA)	11-50	2020	Venture Capital
	Guilford, Connecticut, United States (USA)	51-200	2005	Private
	Hamden, Connecticut, United States (USA)	51-200	2014	Private
	New Haven, Connecticut, United States (USA)	11-50	2020	Private Equity
	New Haven, Connecticut, United States (USA)	1-10	2018	Venture Capital
	New Haven, Connecticut, United States (USA)	11-50	2017	Venture Capital
	Guilford, Connecticut, United States (USA)	1-10	2013	Private
	Norwalk, Connecticut, United States (USA)	201-500	2019	Private
	Fairfield, Connecticut, United States (USA)	11-50	1996	Family Owned
	Milford, Connecticut, United States (USA)	11-50	1990	Private
	Guilford, Connecticut, United States (USA)	11-50	2017	Private
	Stamford, Connecticut, United States (USA)	201-500	2020	Venture Capital
	New Haven, Connecticut, United States (USA)	11-50	2016	Venture Capital
	East Lyme, Connecticut, United States (USA)	51-200	2018	Private
Bexorg, Inc.	New Haven, Connecticut, United States (USA)	11-50	2021	Private
	Madison, Connecticut, United States (USA)	51-200	2016	Private
	Woodbridge, Connecticut, United States (USA)	51-200	1982	Family Owned

Want to Find More Pharmaceuticals Companies?

If you want to find more companies that offer innovative drugs, vaccines, and Å·²©ÌåÓýƽ̨rapeutic solutions to patients you can do so with Inven. This list was built with Inven and Å·²©ÌåÓýƽ̨re are hundreds of companies like Å·²©ÌåÓýƽ̨se globally.

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!